Immix Biopharma Inc — Quarterly Cash Flow (NASDAQ:IMMX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 25.14 M22.95 M19.89 M15.64 M20.08 M Total liabilities 7.59 M9.7 M10.3 M10.98 M11.82 M Total equity 17.55 M13.25 M9.59 M4.65 M8.26 M Total liabilities & shareholders' equities 25.14 M22.95 M19.89 M15.64 M20.08 M Total debt ————— Net debt —————

Haberler

Immix Biopharma hisseleri FDA’nın çığır açan tedavi statüsü vermesiyle yükseldi

FDA, ImmixBio’nun amiloidoz ilacına çığır açan tedavi statüsü verdi

Immix Biopharma stock climbs after FDA grants breakthrough therapy status

FDA grants breakthrough therapy status to ImmixBio’s amyloidosis drug

Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Immix Biopharma (NASDAQ:IMMX)

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX)

Immix Biopharma CFO’su Gabriel Morris 5 bin dolarlık hisse alımı gerçekleştirdi

Ilya Rachman, Immix Biopharma CEO’su 4.975 dolar değerinde hisse satın aldı

Immix Biopharma CFO Gabriel Morris buys $5k in shares

Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares

H.C. Wainwright, Immix Biopharma için hedef fiyatını 8 dolardan 12 dolara yükseltti

Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright